Pharmaceutical Biotechnology Cheat Sheet

The core ideas of Pharmaceutical Biotechnology distilled into a single, scannable reference — perfect for review or quick lookup.

PiqCue — piqcue.com/pharmaceutical-biotechnology/cheatsheet

Quick Reference

Recombinant DNA Technology

A set of molecular biology techniques used to combine genetic material from different sources, creating sequences that would not otherwise be found in nature. In pharmaceutical biotechnology, it enables the production of human proteins in microbial or mammalian host cells by inserting the corresponding gene into an expression vector.

Monoclonal Antibodies

Laboratory-made proteins that mimic the immune system's ability to target specific antigens. They are produced from a single B-cell clone and are identical in structure, providing high specificity and reproducibility for therapeutic use against cancer, autoimmune diseases, and infectious agents.

mRNA Therapeutics

A class of biopharmaceuticals that use synthetic messenger RNA to instruct cells to produce specific proteins, triggering an immune response or replacing a deficient protein. The mRNA is typically encapsulated in lipid nanoparticles for delivery into cells.

CAR-T Cell Therapy

Chimeric Antigen Receptor T-cell therapy is a form of immunotherapy where a patient's T cells are genetically modified ex vivo to express a synthetic receptor that recognizes a specific tumor antigen, then reinfused into the patient to target and kill cancer cells.

Bioprocess Engineering

The design, development, and optimization of manufacturing processes for biopharmaceuticals, including upstream processes (cell culture, fermentation) and downstream processes (purification, formulation). It ensures consistent product quality, yield, and scalability.

Gene Therapy

A therapeutic approach that introduces, alters, or replaces genetic material within a patient's cells to treat or prevent disease. Delivery is typically achieved using viral vectors (adeno-associated virus, lentivirus) or non-viral methods such as lipid nanoparticles.

Biosimilars

Biologic products that are highly similar to an already-approved reference biologic with no clinically meaningful differences in safety, purity, or potency. Unlike generic small-molecule drugs, biosimilars require extensive comparative analytical, nonclinical, and clinical studies due to the structural complexity of biologics.

Pharmacokinetics of Biologics

The study of how biologic drugs are absorbed, distributed, metabolized, and eliminated in the body. Unlike small molecules, biologics are typically administered by injection, have large molecular weights, undergo target-mediated drug disposition, and are catabolized by proteolytic degradation rather than hepatic metabolism.

CRISPR-Cas9 Gene Editing

A genome editing technology that uses a guide RNA to direct the Cas9 nuclease to a specific DNA sequence, where it creates a double-strand break. The cell's repair mechanisms can then be harnessed to knock out a gene, correct a mutation, or insert new genetic material.

Antibody-Drug Conjugates (ADCs)

A class of targeted cancer therapeutics that combine a monoclonal antibody linked to a cytotoxic drug (payload) via a chemical linker. The antibody delivers the potent chemotherapy agent directly to cancer cells expressing the target antigen, minimizing systemic toxicity.

Key Terms at a Glance

Adeno-Associated Virus (AAV):A small, non-enveloped virus commonly used as a vector for gene therapy due to its low pathogenicity and ability to infect both dividing and non-dividing cells.

Antibody-Drug Conjugate (ADC):A targeted therapy combining a monoclonal antibody linked to a cytotoxic drug payload via a chemical linker for selective delivery to antigen-expressing cells.

Bioavailability:The fraction of an administered dose of drug that reaches the systemic circulation in an unchanged form. For biologics administered subcutaneously, bioavailability typically ranges from 50-80%.

Bioreactor:A controlled vessel for growing cells or organisms to produce biopharmaceutical products, with regulation of temperature, pH, dissolved oxygen, and nutrient supply.

Biosimilar:A biologic product demonstrated to be highly similar to an approved reference biologic with no clinically meaningful differences in safety, purity, or potency.

CAR-T Cell Therapy:A personalized immunotherapy in which a patient's T cells are engineered to express a chimeric antigen receptor targeting a specific tumor antigen, then reinfused to attack cancer cells.

CHO Cells:Chinese Hamster Ovary cells, the most widely used mammalian cell line for large-scale industrial production of recombinant therapeutic proteins, particularly monoclonal antibodies.

CRISPR-Cas9:A genome editing system using a guide RNA to direct the Cas9 endonuclease to a specific genomic locus, enabling precise gene knockout, correction, or insertion.

Critical Quality Attribute (CQA):A physical, chemical, biological, or microbiological property that should be within an appropriate limit to ensure the desired product quality of a biopharmaceutical.

Downstream Processing:The purification and formulation stages of biopharmaceutical manufacturing following cell culture, including chromatography, filtration, viral clearance, and fill-finish operations.

Expression Vector:A DNA construct (plasmid or viral genome) designed to carry and express a gene of interest in a host cell, containing promoters, selection markers, and other regulatory elements.

Fc Region:The crystallizable fragment of an antibody that interacts with cell surface receptors and complement proteins, mediating effector functions and determining serum half-life through FcRn binding.

Glycosylation:The enzymatic post-translational modification that attaches oligosaccharide chains to proteins, critically affecting folding, stability, function, and immunogenicity of biopharmaceuticals.

Good Manufacturing Practice (GMP):Regulatory guidelines ensuring that pharmaceutical products are consistently produced and controlled according to quality standards, covering all aspects from raw materials to final product release.

Immunogenicity:The propensity of a therapeutic protein to generate an immune response, including anti-drug antibodies, which can affect drug efficacy, pharmacokinetics, or patient safety.

Get study tips in your inbox

We'll send you evidence-based study strategies and new cheat sheets as they're published.

We'll notify you about updates. No spam, unsubscribe anytime.